• Journal of Periodontal and Implant Science
• /
• v.36 no.1
• /
• pp.179-194
• /
• 2006

목적 : 이번 연구에서는 일반인의 치주질환 치료제에 대한 인식도를 설문을 통하여 알아보았고 현재 국내에서 시판중인 치주질환, 치료제를 의약품 검색 사이트를 이용하여 조사하였다. 조사한 치료제의 효과를 해당 약품의 성분과 관련된 문헌을 고찰함으로써 알아보았다. 재료 및 방법 : 일반인의 치주질환 치료제에 대한 인지도를 조사하기 위하여 열 개의 문항으로 구성된 설문을 실시하였다. 설문은 한림대학교 성심병원 산업의학과에 정기 건강검진을 위하여 내원한 사람들을 대상으로 하였다. 보건복지부에 등록된 치주질환 치료제를 조사하기 위하여 킴스 온라인 홈페이지를 이용하였다. 의약품 종합 검색 페이지에서 '추가조건 입력하기'의 '복지부 분류'란에 '231. 치과-구강용약'의 조건을 주어 검색하였다. 검색 결과로부터 경구 치주질환 치료제를 구별하여 정리하였다. 치주질환 치료제와 관련된 문헌을 조사하기 위하여 미국 국립도서관의 검색 서비스인 Pubmed 홈페이지를 이용하였다. 검색어는 각 지료제의 성분명과 치은염, 치주염, 치주질환의 조합어를 사용하였다. 결과 : 설문에 참여한 사람은 100명이었다. 이 중 85%는 치주질환이라는 말을 들어본 적이 있었으며 72%는 자신의 치주건강상태가 좋지 않다고 생각하였다. 14%는 치주질환 치료제를 복용한 경험이 있었다. 61%는 치주질환 치료제에 관한 정보를 광고로부터 획득하였다. 향후 치주질환 치료제의 선택과 관련하여 35%는 치과의사에게, 24%는 의사에게 그리고 20%는 약사에게 문의하겠다고 대답하였다. 치주질환 치료제는 70개였다. 이 중 38개는 아스코르빈산 제제, 25개는 옥수수 불검화 추출물 제제, 5개는 저용량 독시싸이클린 제제였고 아보카도-콩 불검화물과 동양의학적 제제가 각각 한 개였다. 결론 : 치주질환 치료제에 대한 일반인의 인지도는 비교적 낮았으며 정보를 획득하는 주요 경로는 광고였다. 일반인들이 치주질환 치료제를 선택하는 데 치과의사는 큰 역할을 하지 못하였다. 시판중인 치주질환 치료제는 70개였다. 치료제는 다섯 개의 군으로 분류할 수 있었으며, 아스코르빈산 제제, 옥수수 불검화 추출물 및 저용량 독시싸이클린이 대부분이었고 아보카도-콩 불검화물과 동양의학적 제제는 각각 한 개였다. 옥수수 불검화 추출물과 저용량 독시싸이클린은 임상 연구에 의해 그 효과가 입증되었으나 아스코르빈산 제제는 임상 연구가 없었으며 따라서 이상적인 제제라고 할 수 있다. 기존의 문헌에 기초하여 볼 때 옥수수 불검화 추출물과 저용량 독시싸이클린만이 전통적인 치주질환 치료법(SRP)과 병행하여 치료제로 사용될 수 있다.

• Journal of Periodontal and Implant Science
• /
• v.32 no.4
• /
• pp.847-855
• /
• 2002

It has been reported that Magnoliae cortex extract has antibacterial and antimicrobial activity against pathogenic microbes and Zea Mays L. extract is effective for improving gingival tissue health. The purpose of this study was to examine the anti-inflammatory and antimicrobial effects of Zea Mays L. and Magnoliac cortex extract mixtures through experimental peridontitis induced beagle dog model. Nine beagle dogs with experimentally induced periodontitis were selected. Baseline clinical indices which includes plaque index, gingival index, probing pocket depth, clinical attachment level, gingival fluid flow rate were recorded and microbial assays were done. Magnoliac cortex and Zea Mays L., mixed at 2:l ratio in 105mg capsular dosage, were taken by 3 capsule (Group I) or 6 capsule dosages (Group II) three times a day. After 4,8,12 weeks, clinical indices were recorded. All data of clinical indices were compared through one-way ANOVA with 95% confidence level. Clinical indices of group I and II showed significantly better results than those of control group. There were no significant differences between group I and II. In conclusion, it was confirmed that mixture of Magnoliae cortex and Zea May L. (mix ratio 2:1) possessed clinical improving effects to periodontitis.

• Journal of Periodontal and Implant Science
• /
• v.32 no.1
• /
• pp.249-255
• /
• 2002

Zea Mays L. has been known to be effective for improving tissue health and Magnoliae cortex to have effective antibacterial and antimicrobial activity against pathogenic microbes. The purpose of this study was to examine the antimicrobial effects of Zea Mays L. and Magnoliae cortex extract mixtures on periodontal pathogens(Prevotella intermedia, Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis, Streptococcus mutans )and to examine the effects on human gingival fibroblast cellular activity. Zea Mays L. and Magnoliae cortex extracts and their mixtures were prepared with various mixing ratios (0.5:1, 1:1, 1.5:1, 2:1). These extracts were loaded to periodontal pathogen cultured petri dish for antimicrobial test and also loaded to cultured human gingival fibroblast for cellular activity test. Each test was repeated 3 times and data were analyzed by one-way ANOVA with 95% confidence level. Mixture of these two extracts showed greater amount of inhibition area on periodontal pathogen and more improved gingival fibroblast activity as Zea Mays L. ratio reduced. So, mixture ratio 0.5:1 (Zea Mays L. : Magnoliae cortex) group showed statistical significance in antimicrobial activity and cellular activity among various mixtures(p < 0.05). In conclusion, 0.5:1 (Zea Mays L. : Magnoliae cortex) mixture possessed best gingival fibroblast cellular activity and antimicrobial activity toward periodontal pathogens.

• The Journal of the Korean dental association
• /
• v.53 no.7
• /
• pp.476-484
• /
• 2015

Purpose: This study intended to analyze the validity of clinical effectiveness data of clinical trials testing systemic titrated extract of Zea Mays L. unsaponifiable fraction chemotherapeutic agent. Material and Methods: Among 5 clinical trials claimed as proof of clinical effectiveness on the Web site of the manufacturer of this chemotherapeutic agent, a review of 4 clinical trials, written in either Korean or English, was conducted. Data were extracted from studies for the following variables: year of publication, age, sample size, follow-up period, combination with contemporary periodontal treatments, randomization, randomization check, blinded measurement, and statistical test type. Results: The study subjects' age intervals were too diverse to decide a common target population to generalize the findings. No study stated clearly the rationale for the sample size determination. Follow-up period to observe the start of clinical effectiveness was inconsistent and decided without any rationale of pathophysiological latent period. Randomization to make the comparisons on the same start line was performed but failed in a study. Randomization effect was not checked in 4 studies. Performance of blinded measurement of clinical outcomes to prevent bias was unclear in 2 studies. Type of statistical test was inappropriate in 3 studies. Conclusions: Based on the analysis of the validity of data on clinical and demographic variables, the four available clinical trials have not demonstrated compelling evidence of therapeutic effectiveness of systemic titrated extract of Zea Mays L. unsaponifiable fraction chemotherapeutic agent to improve prognosis of periodontal disease either with the contemporary periodontal treatment or without it.

• Journal of Periodontal and Implant Science
• /
• v.32 no.2
• /
• pp.403-414
• /
• 2002

I. Purpose of Study Zea Mays L. has been known to be effective for improving periodontal health and Magnoliae cortex to have effective antibacterial and antimicrobial activity against periodontal pathogens. The purpose of this study was to examine the biologic effects of Zea Mays L. and Magnoliae cortex extract mixtures on healing of rat calvarial bone defects. II. Materials & Methods 8mm circular defects were prepared on rat calvaria during surgical procedures of 180 Sprague-Dawley rats. The ethanolic extracts of Magnoliae cortex and Zea Mays L. and these two natural extract 1:1 and 2:1 (Magnoliae: Zea Mays L.) ratio mixtures were oral administrated by oral zondes once a day at two different dose of 94.5mg/kg, 189mg/kg body weight. There are nine groups of rats in this study: control group (no sample loading), Magnoliae cortex extract loading groups (I,II)(94.5mg/kg,189mg/kg respectively), Zea Mays L. extract loading groups (I,II), M:Z(1:1) loading groups (I,II), M:Z(2:1) loading groups(I,II). Rats were sacrificed at 4 weeks and 6 weeks after surgery. New bone formations around calvarial defects were radiographically and histologically measured by computerassisted histomorphometry. Each data was statistically analyzed by One-way ANOVA test. III. Results There were statistical significances between negative control group and the other test groups on radiographical and histological quantitative assessments. Among test groups, mixture groups showed statistical significances, especially, M:Z (2:1) groups (I and II) were highly significant.(p<0.05) These results implicated that the mixture of Magnoliae and Zea Mays L. (2:1 mixing ratio) with 94.5mg/kg concentration might be highly effective on the wound healing of bony defected site and have potential possibilities as a useful drug to promote bone tissue regeneration.